Peterson ED, et al. - In 3,563 propensity score-matched pairs of morbidly obese atrial fibrillation (AF) patients treated with rivaroxaban or warfarin in two US healthcare claims databases, researchers compared ischemic stroke/systemic embolism and major bleeding risk, as well as healthcare resource utilization and costs, using conditional logistic regression and generalized linear models. Excluding patients who had mitral stenosis, a mechanical heart valve procedure, an organ/tissue transplant, or an oral anticoagulant prescription prior to the index date, they included patients initiating rivaroxaban or warfarin who had ≥ 1 medical claim with an AF diagnosis, a diagnostic code for morbid obesity, and a minimum continuous enrollment of 12 months prior to—and 3 months following—treatment initiation. In terms of risk of ischemic stroke/systemic embolism and major bleeding, comparable outcomes were provided by rivaroxaban vs warfarin in morbidly obese AF patients. Treatment with rivaroxaban vs warfarin resulted in lower healthcare resource utilization and costs in this patient population.